In studying the age dependence and chronology of ovarian tumors in follicle stimulating hormone receptor knockout mice, we identified a novel ovarian tumor associated gene-12 (OTAG-12), which is progressively downregulated and maps to Chr. 8B3.3. OTAG-12 protein overexpression in mouse ovarian and mammary tumor cells suggested powerful anti-proliferative effects. In human epithelial ovarian cancers (OCs) and OC cell lines, OTAG-12 mRNA expression is downregulated in comparison with normal ovaries. Cloning and identification revealed that human OTAG-12 mapping to gene-rich Chr. 19p13.12 is expressed in three spliced forms: hOTAG-12a, hOTAG12b and hOTAG-12c, of which b is predominant in the normal ovary. Functionally active hOTAG-12b is a simple protein with no disulfide bonds and a nuclear localization signal is present in all variants. Transfection of OTAG-12 variants in OC and tumorigenic HEK293 cells confirmed nuclear localization. hOTAG-12b overexpression in OC and HEK293 cells effectively suppressed cell growth, anchorage-dependent and independent colony formation followed by apoptosis, whereas hOTAG-12a and hOTAG12c had no such effects. Deletion mutants identified the critical importance of carboxyl terminus for hOTAG-12b function. Doxycycline-inducible growth inhibition of HEK293 cells by hOTAG-12a was associated with effects on G2 cell cycle arrest and apoptosis induction. hOTAG12b expression rendered tumorigenic cells more sensitive to four apoptotic stimuli including etoposide-a topoisomerase-II inhibitor. Doxycycline-induced hOTAG-12b expression blocked xenograft tumor growth in nude mice, whereas hOTAG-12a was ineffective. Although p53-pathway-dependent apoptotic agents could upregulate endogenous hOTAG-12b and p53 in UCI-101/107 OC cells, hOTAG-12b could also induce apoptosis in p53-null and platinum-resistant SKOV3 OC cells and Doxycyclineinduced hOTAG-12b did not alter p53. Further study showed that hOTAG-12b increases mRNAs of proapoptotic genes such as BAD, GADD45a and CIEDB, while inhibiting anti-apoptotic NAIP and Akt1 expression, suggesting that hOTAG-12b-induced apoptosis might be p53-independent. These results indicate that hOTAG-12b is a putative ovarian tumor suppressor gene warranting further studies.
Introduction
Ovarian cancer (OC) is the most aggressive cancer and leading cause of death from gynecological malignancies in the developed world, with an incidence of about 190 000 new cases and 114 000 fatalities (Jemal et al., 2009) . Although OC accounts for only 4% of all cancers in women, it is 3 Â more lethal than breast cancer. Epithelial OC (EOC), which accounts for 85% of OC in post-menopausal women, is believed to originate from cells of the aberrant ovarian surface epithelium or fimbriated region of the fallopian tube (Jarboe et al., 2008) . Around 10% of OCs are associated with mutations of BRCA1 and BRCA2 (Pal et al., 2005) , although multiple genetic and epigenetic abnormalities have been detected in different individuals. Despite improvements in cytoreductive surgery and the initially favorable response to platinum-based chemotherapies, nearly two-thirds of the patients succumb within 5 years of diagnosis (Konstantinopoulos et al., 2008) . Most patients are initially diagnosed at advanced stages and there are no reliable prognostic markers for predicting clinical response and guiding treatment of drug-resistant cancers. Knowledge of novel genes and molecular targets expressed in ovarian tumors is required for better and early detection and development of new therapies (Bast Jr et al., 2009) .
Tumor suppressor genes have key roles in cell growth, proliferation, apoptosis and tumor development (Bruening et al., 1999; Luo et al., 2003; Bignone et al., 2007; Bast et al., 2009 ). Sixteen candidate tumor suppressor genes have been studied in OC (Bast Jr et al., 2009) . EOC is a heterogeneous disease with complex pathology and more than 50% of high-grade serous-type EOCs contain p53 mutations and alterations in the retinoblastoma (RB) pathway (Corney et al., 2008; Bast Jr et al., 2009) , whereas K-Ras, Pten and Wnt/b-catenin are implicated in endometrioid OC subtype (Dinulescu et al., 2005; Wu et al., 2007) .
In studies with tissues or cells from late-stage OCs, it has been difficult to segregate molecular changes related to disease initiation from other factors like progression and drug treatment. As knowledge of early tumorigenic events and genes is urgently needed, these issues can be studied systematically in models that can be experimentally manipulated to capture chronological changes. Thus we reported that in follitropin receptor knockout (FORKO) mice with sex hormone imbalances, females develop age-dependent ovarian tumors by B12 months (Danilovich et al., 2001; Chen et al., 2007) . Tracking early and progressive ovarian tumorigenic events in this model revealed the pattern of molecular changes also found in EOC in women, including claudins, E-cadherin and platelet-derived growth factor (PDGF) ligands and receptors, as well as immune system upregulation in pretumor stages (Chen et al., 2006; Aravindakshan et al., 2006a, b) . We then hypothesized that transcriptome comparison at different stages could lead us to implicate novel and unknown genes in ovarian tumor development. Herein we focus on one novel gene that was progressively downregulated in pre-tumor and tumorbearing mutant ovaries and was also very low in mouse epithelial tumors. This novel ovarian tumor-associated gene-12 (OTAG-12) was cloned from both mouse and human ovaries and evidence is presented for its antiproliferative and proapoptotic effects in OC cells. Only one of three alternatively spliced forms of human exhibits potent inhibitory effects on OC cells by p53-independent mechanisms. As overexpression of hOTAG-12b sensitizes tumorigenic cells to the apoptotic action of other anti-cancer agents, there could be potential for devising recombinant therapeutic modalities for mitigating tumor burden.
Results
Transcriptome analysis and discovery of novel gene OTAG-12 To find novel genes during ovarian tumorigenesis, we compared the transcriptome in 1-month, 8-month (pretumor) and 12-month-old (tumor-bearing) FORKO and wild-type littermates (Aravindakshan et al., 2010) . Among transcripts dysregulated X2-fold, we focused exclusively on unknown genes. Using bio-informatics data to deduce predicted open reading frames (ORFs) for hypothetical proteins, we attributed significance if the gene was conserved in humans. Second, we stipulated ovarian expression and disease association, as in FORKOs. Third, we chose predicted proteins that could help test function. Thus, one expressed sequence tag (EST) identified by Affymetrix probe, '1423216_a_at', was selected, as this gene showed progressive decrease from pre-tumor stage to ovarian tumors at 12 months ( Figure 1a) . BLASTN search matched this with an uncharacterized transcript: Mus musculus RIKEN cDNA 2510049I19Rik. We named the gene as OTAG-12 to stand for ovarian tumor associated gene-12. Quantitative PCR (Q-PCR) confirmed OTAG-12 alteration in FORKO ovary (Figure 1b) . Expression was decreased to 30% (Po0.05) at 12 months in FORKO tumors (Figures 1a and b) consistent with microarray. Maximal downregulation was found in syngenic peritoneal ovarian epithelial tumors grown using mouse ID8 cells (Roby et al., 2000) . In female mice, OTAG-12 mRNA was also expressed in several other tissues at varying levels ( Figure 1c ).
Cloning of mouse and human OTAG-12 genes and protein characteristics Cloning and identification of mouse ORF confirmed 100% match to hypothetical protein LOC67922, mapping to murine chr. 8 B3.3. The 4046-bp mouse OTAG-12 gene has four exons. The 1921-bp cDNA codes for a protein of 112 amino acids ( Figure 2a ). We then performed 3 0 /5 0 rapid amplification of cDNA ends PCR (RACE-PCR) to secure full-length human OTAG-12 of 1463 bp. Except for deletion of the last A (Supplementary Figure 1 ), the sequence determined matches hypothetical cDNA (NM_014077.2). This full-length cDNA includes a 339-bp ORF (LOC26017) containing ATG codon in EXON 1 within a good Kozak consensus sequence (GTCATGG). A 3 0 -UTR polyadenylation site (AATAAA) lies 1068 bp downstream of the stop codon and 19 bp upstream of a poly (dA) tail. Human OTAG-12 gene spanning 6.6 kb maps to chr. 19p13.1 and is located near a cluster of known OC-related genes (Figures 2b and c) . The amino-acid sequence of human ovarian OTAG-12 shows high homology to mouse (97%) (Figure 2e and other species (Supplementary Figure 2) ), indicating conservation. Both mouse and human have a nuclear localization signal peptide KRKKKKKDK; this location was confirmed by immunohistochemistry ( Figure 3e ). Functional motifs search of OTAG-12 protein indicated potential sites for protein-DNA binding, phosphorylation and interactions with 14-3-3 (Figures 2e and f) .
Isoforms of human OTAG-12
When human OTAG-12 was amplified by PCR using primer pairs flanking the hypothetical ORF, two or more bands were evident (Figure 2d ). The major amplicon b corresponds to the predicted ORF of 339 bp and referred herein as hOTAG-12b (Figures 2c  and d) . The higher amplicons correspond to isoforms a and c. Their identity as hOTAG-12a (variant 1 in data bank) and 12c (variant 3) in the normal ovary was confirmed by using ORF-specific primers and sequencing. As variants in mouse ovary are minor (Figure 2c ), we pursued only the major form. Human (and mouse) OTAG-12b proteins are basic, with 112 amino acids containing no cysteine residues or glycosylation site. However, hOTAG-12a with 107 residues, while still basic, has two cysteines that could alter its properties. hOTAG-12c comprising 92 amino acids also differs from hOTAG-12b but at the N-terminus (Figure 2f ).
Expression of OTAG-12 in human ovarian tumors and OC cell lines By designing primers (Supplementary Table 1 ) based on our cloning data, we verified expression in normal ovary and human EOCs using Q-PCR. These analyses were done in a blinded manner. The dominant form, hOTAG-12b, in normal ovary was significantly downregulated in OC (Figure 3a) . The relative expression of OTAG-12 in normal human ovary appears to be hOTAG-12bc12ap12c. Whereas the expression of hOTAG-12a is not significantly altered in OC, hO-TAG-12C also appears to be downregulated (see Supplementary Figure 3) . In five human OC cell lines, hOTAG-12b expression was lower than in normal ovary Figure 1 Chronology of mouse OTAG-12 expression in ovary, FORKO, various tissues and apoptotic induction of mouse ID8 and HC11-26 mouse mammary cells (Dievart et al., 1999) . (a) Microarray data of OTAG-12 expression in FORKO and age-matched wildtype (WT) females at 1 month, 8 months and 12 months. (b) Q-PCR analysis of mouse OTAG-12 in ovarian samples of 12-month-old WT, age-matched FORKO, ovarian tumor and mouse epithelial tumor nodules, normalized to b-actin (n ¼ 3 mice). The tumor nodules were generated by injecting cultured mouse tumorigenic cell line ID8 into 3-month-old FORKO females and collecting the peritoneal tumors after 2-3 months. *Po0.05; **Po0.01, significant difference. (c) Mouse OTAG-12 expression in different tissues of 4-5-month-old female mice. The expression level of wild-type ovary, set as 1 unit, is normalized by b-actin (n ¼ 3 mice). (d) Western blot of mouse OTAG-12. Cells were transiently transfected with OTAG-12 cloned into pIRES2-V5-EGFP vector. After 24 h, cells were washed by PBS and lysed by RIPA lysis buffer and 20-50 mg of lysate was used for western blotting. The mouse anti-V5 antibody (Cat. No. R960-25, Invitrogen) was used at 1:8000 dilution to detect tagged OTAG-12 protein. The 17-kDa band shown represents OTAG-12. (e) OTAG-12 overexpression inhibits colony formation. 10 6 cells were seeded, transfected and grown in selection media (700 mg/ml G418 for ID8 cells and 600 mg/ml G418 for HC11-26 cells) for 2-3 weeks. Colonies were stained with Coomassie blue (0.1% Coomassie blue, 30% methanol, 10% acetic acid) and photographed. (f) Colonies formed were counted and the results of three different experiments in triplicate were combined; the bar graph shows the mean±s.e. Colony numbers in OTAG-12 were compared with empty pRIS2-EGFP vector after transfection; significant differences were observed. ***Po0.001. The sequence of mouse and human OTAG12 proteins are as deduced from our current cloning work on ovarian tissue. The nuclear localization signal in OTAG12 is indicated by a line on top of the sequence, and the 3-75 region is a conserved domain called DUF1754, whose significance is unknown. Predicted structural motifs by http:// elm.eu.org/in hOTAG-12 are indicated. Domains MAPK 1 (Johnson and Lapadat, 2002) , FHA2 (Schwartz et al., 2003), 14-3-3 (Dougherty and Morrison, 2004) , USP7 (Maertens et al., 2010) binding sites as well as DNA-binding sites are shown in bold. The predicted OTAG-12 proteins with accession numbers for other species are shown in Supplementary Figure 2. (f) Alignment of three variants of human OTAG-12a, b and c. In all, 73 amino acids in the N-terminal are the same between hOTAG-12a and hOTAG-12b, whereas 88 amino acids in the C-terminal are the same between hOTAG-12b and hOTAG-12c. Importantly, a potential -SÀSÀ bridge is likely to be present only in OTAG-12a. Note the differences between hOTAG-12b and 12a (see Supplementary Figure 2 ).
Novel ovarian tumor suppressor gene X Chen et al ( Figure 3b ). hOTAG-12b expression in surgically removed normal human ovarian cortex used as a surrogate for OSE was similar to that in normal ovary. Expression in HEK293 cells was slightly higher. Perusal of public microarray expression data using Affymetrix probes (http://symatlas.gnf.org/SymAtlas/ http://biogps.gnf. org/#goto ¼ genereport&id ¼ 26017) indicates OTAG-12 expression in a variety of human tissues.
Effects of overexpression of OTAG-12 on OC, mammary and tumorigenic HEK293 cells
To explore the possible involvement of the novel gene in cell growth, we first transfected mouse pIRES2-OTAG-12-V5-GFP into mouse ID8 and HC11-26 mammary cancer cells (Dievart et al., 1999) . Transient transfection revealed the corresponding protein in the cell lysate ( Figure 1d) ; however, within 5 days cell proliferation
Novel ovarian tumor suppressor gene X Chen et al was inhibited (Figures 1e and f) . Mouse OTAG-12 also inhibited anchor-independent cell growth (not shown).
We extended the studies to all three human OTAG-12 variants on three OC and tumorigenic HEK293 cells. Only hOTAG-12b but not the isoforms -12a and -12c (not shown) inhibited growth and induced apoptosis in the cells (Figure 3c ). Assessment of anchorage-dependent cell growth or independent colony formation showed hOTAG-12b alone to exert potent cell suppression ( Figure 3d ).
Subcellular localization of OTAG-12 proteins
Immunohistochemical probing using V5-tag showed predominant hOTAG-12b and 12a localization in the nucleus (Figure 3e ) of UCI107 OC cells. By western blotting, the hOTAG-12b and -12a proteins were also found only in the nuclear fraction ( Figure 3f ).
Importance of the C-terminal sequence of hOTAG-12b for function As hOTAG-12b protein differs from hOTAG-12a in the carboxyl terminus, we reasoned that domains in this region could be important for biological function. To verify this, we constructed deletion mutants and tested them as shown in Figure 4 . Deletion of the UP domain produced significant but incomplete suppression. However, further deletion of the F14 domain as in hOTAG-12bDC21 abolished cell-suppressing activity ( Figures 4C and D) . Equivalent protein expression of (Fuchtner et al., 1993; Gamboa et al., 1995) and others from ATCC. OTAG-12b expression level of all OC cells is lower than hOVC and normal ovary. (c) Overexpression of hOTAG-12b reduces anchorage-dependent colony formation (relative number of colonies; control vector taken as 100) in four cell lines. At 24 h after transient transfection, cells were trypsinized, washed, 1:20 diluted and grown in six-well plates in selection media containing G418. Cells were grown for 2-3 weeks; colonies were stained with Coomassie blue (0.1% Coomassie blue, 30% methanol, 10% acetic acid) and counted. At least three experiments were performed in quadruplicate for each cell line. ***Po0.001. (d) Soft agar assays. We mixed 5 Â 10 4 cells at 37 1C with 0.4% agarose in complete medium and poured the mixture over a layer of 0.8% agarose in complete medium in six-well plates. The top layer was allowed to gel at room temperature for at least 15 min, and the plates were then incubated at 37 1C for 2-3 weeks with or without G418. At the end, the plates were stained by adding p-iodonitrotetrazolium violet to each well and incubated at 37 1C for 6 h, after which the colonies were photographed with a Zeiss microscope and counted by using a software associated microscope. Colony numbers in hOTAG-12b were compared with hOTAG-12a and empty pIRES2 vector transfection; significant differences were observed for UCI107. The soft agar result is consistent with the result of anchorage-dependent cell growth. The image is representative of at least three separate experiments. (e) Localization of hOTAG-12a and hOTAG-12b by using V5 antibody in human OC cell line UCI107. Both hOTAG-12a and hOTAG-12b are predominantly localized in the nucleus. (f) Nuclear fractions (40 mg) of transiently transfected UCI101/107 cells with hOTAG-12a, hOTAG-12b or vector each were analyzed by western blot with V5 antibody. The arrow shows apparent molecular weight.
all mutants except DC37 (slightly reduced) was confirmed by western Blot and IHC using the V5 antibody ( Figure 4B ).
Inducible expression of hOTAG-12 in HEK293 cells
As hOTAG-12b's effects in transfected cells were dramatic, we were unable to establish stable cell lines constitutively expressing hOTAG-12b in all tested cells. Therefore, we tried to establish doxycycline (DOX)-inducible stable cell lines expressing OTAG-12s using OC cells and HEK293 cells. Under identical conditions, we succeeded only in securing stable clones of the more easily transfectable HEK293 cell line but not OC cells. Hence, all studies on DOX-induced expression could henceforth be conducted using stable HEK293 cells. As shown in Figure 5A , hOTAG-12b expression under DOX induction varied in different clones; fewer cells survived in the highest inducible hOTAG-12b subclonec33. Clone 32 with lowest expression retained better growth, with clone c25 being intermediate. In hOTAG12b-c33, clone induction with 1.6 mg/ml DOX showed potent suppression with minimal toxicity (Figures 5Ba-f ). However, cell growth continued upon DOX induction of hOTAG-12a or vector control. The level of hOTAG-12 could be controlled by varying DOX ( Figure 5C ); hOTAG-12a and hOTAG-12b were inducible to similar levels within 24 h, reaching a steady state by 2À3 days ( Figure 5D ).
To verify that hOTAG-12b was not toxic to cells, we first induced hOTAG-12b expression for a day or two; when cell (A) Schematic presentation of hOTAG-12a (107 residues), hOTAG-12b wild-type (112 amino acids) and its deletion mutants. hOTAG-12b DC10: deletion mutant lacking the last 10 amino acids (UP domain) of hOTAG-12b; hOTAG-12b DC21: deletion mutant lacking the last 21 amino acids (UP and F14 domains) of hOTAG-12b; hOTAG-12b DC37: deletion mutant lacking the last 37 amino acids of hOTAG-12b; NLS: nuclear localization sequence; F14: predicted binding sites of FHA-2 and 14-3-3; UP: predicted binding site of USP-7 (ubiquitin-specific peptidase 7). (B) Immunohistochemical staining of transiently transfected tumorigenic HEK293 cells by different constructs using V5 antibody (top). a: hOATG-12a; b: hOTAG-12b wild type; c: hOTAG12b DC10; d: hOTAG-12b DC21; e: hOTAG-12b DC37; f: vector. Immunoblot profiles of expression of hOTAG-12a, and hOTAG-12b wild-type and mutants in transfected cells probed with V5 tag antibody (bottom). Expression level of hOTAG12bWT and mutants hOTAG-12b DC10 and hOTAG-12b DC21 is similar, but hOTAG-12b DC37 expression appears to be low. (C) Effect of hOTAG-12a, and hOTAG-12bWT and its deletion mutants on HEK293 cells. Cells were transfected with same amount of plasmids and after 24 h diluted 1:20 into the selection medium containing 700 mg/ml G418 and incubated for 8 days. Cells were then stained by Coomassie Blue. a: vector; b: hOATG-12a; c: hOTAG-12b wild-type; d: hOTAG-12b DC37; e: hOTAG-12b DC21; f: hOTAG-12b DC10. (D) Quantification of the cell staining of hOTAG-12a, and hOTAG-12b wild-type and mutants. Each bar indicates ± s.e.m. The results show that hOTAG-12b wild-type could induce cell death, mutant hOTAG-12b DC10 could suppress the cell growth, but hOTAG-12a, hOTAG-12b DC21 and hOTAG-12b DC37 have no effect, suggesting that F14 domain of hOTAG-12b is critical for inducing cell death. At least three expriments were performed, **Po0.01; ***Po0.001.
Novel ovarian tumor suppressor gene X Chen et al growth was greatly suppressed by hOTAG-12b, we washed out DOX from the medium and reseeded the remaining cells at the original density. In cells limited to 1-day DOX exposure, hOTAG-12b mRNA started to decrease on day 2 and was similar in amount to the untreated cells at day 3 ( Figure 5F ). Correlating with hOTAG-12b level, cells pre-exposed to hOTAG-12b for 1 day resumed growth relatively quickly ( Figure 5E ); cells exposed to the 2-day effects of hOTAG-12b induction resumed growth after a lag period. Thus, growth inhibition is dependent upon hOTAG12b expression level and induction effects are reversible.
OTAG-12 suppresses cell growth
The effects of hOTAG-12a and -b on cell proliferation were further examined by MTT assay. Cells with vector, hOTAG-12a or hOTAG-12b were seeded at the same density and cultured in the absence or presence of 1.6 mg/ml DOX for 5 days. Compared with vector and hOTAG-12a, the growth rate of hOTAG-12b-inducible stable cells was significantly slower (Figure 6a ). After 4-5 days, very few hOTAG-12b-expressing cells survived.
hOTAG-12b influences the cell cycle Addressing the mechanism of growth suppression, we examined cell cycle progression using an inducible clone of cells. As illustrated in Figure 6b , about 30% increase in the G2 population was observed only when hOTAG12b was induced by DOX, suggesting that hOTAG-12b exerted its effects on cell cycle progression by inducing G2 arrest.
hOTAG-12b induces cell apoptosis To investigate whether hOTAG-12b could regulate apoptosis and cause cell death, we performed several tests. Annexin-V APC detection (Figures 7a and b) revealed that apoptosis was significantly increased in cells expressing exogenous hOTAG-12b 3 days after DOX treatment (Po0.01) compared with controls. Apoptosis was evident as early as 2 days (not shown). We found no significant apoptosis in cells expressing hOTAG-12a or vector. Hematoxylin and Hoechst 33342 staining (Figure 7c ) showed morphological features of hOTAG-12b-triggered cell death as early as 66 h. In contrast, most cells were viable in the absence of DOX. The increase of dead cells correlated with the decrease of live cells, suggesting that cell death was the major mechanism for growth suppression. Assessing the DNA ladder, we found typical changes on day 3 of DOX treatment in hOTAG-12b cells but not in hOTAG-12a and vector (Figure 6d ). Anchorage-independent assays confirmed the above results. No colony was detected in Novel ovarian tumor suppressor gene X Chen et al HEK293 hOTAG-12b under DOX induction. In control cells, containing only repressor plasmid or hOTAG-12a, DOX had no effect (Figures 7e and f) .
hOTAG-12b overexpression inhibits tumor growth in nude mice
We then examined the effects of hOTAG-12 on in vivo tumor growth in xenografted nude mice. Stable and DOX controlled vector, hOTAG-12a and hOTAG-12b-c25/ c33 lines were injected into nude mice (Figures 7g and h ). Control mice without DOX developed visible and solid tumors, indicating vigorous growth in 4 weeks ( Figure 7g) ; DOX treatment from day À1 selectively blocked tumors at sites where hOTAG-12b-expressing cells were injected. The blockade was more effective at sites where cells with a higher level of hOTAG-12b (OTAG-12b-H) were injected as compared with sites with a lower level of hOTAG-12b-L cells (Figure 7h ). Overall these results indicate that tumor growth in vivo could be controlled by regulated expression of hOTAG-12b. Histology of the excised tumors confirmed the inhibitory effects of hOTAG-12b (see Supplementary Figure 4 ).
Potential apoptotic pathways affected by hOTAG-12b in OC cells
OC cells were treated with apoptotic drugs including etoposide, puromycin, carboplatin, taxol and hygromycin-B. The first three use a p53-dependent mechanism, whereas the latter two trigger p53-independent apoptosis. Following treatment, the OTAG-12b increase in UCI 107/101 OC cells paralleled p53 changes induced by etoposide, puromycin and carboplatin, whereas both taxol and hygromycin-B did not upregulate hOTAG12b or p53 (Figure 8a ). This suggested that upregulation of endogenous expression of hOTAG-12b and p53 induced by etoposide, puromycin or carboplatin could be contributing to their apoptotic effects in OC cells. In p53-null SKOV3 OC cells resistant to various agents, transfection of hOTAG-12b but not hOTAG-12a caused cell loss (Figure 8b ), suggesting that overexpression of hOTAG-12b alone in the absence of wild-type p53 is sufficient to trigger apoptosis. To explore the downstream apoptotic events activated by hOTAG-12b, we verified several genes (Supplementary Table 2 ) in cells with DOX-controlled hOTAG-12b. In this study, pro-apoptotic genes such as GADD45a, CIDEB and BAD increased, whereas anti-apoptotic NAIP and proliferation promoter Akt1 decreased (Figure 8c ), suggesting cumulative effects: increasing pro-apoptotic and decreasing anti-apoptotic genes. Notably, GADD45a, CIDEB and BAD increased as early as after 12-24 h of hOTAG-12b exposure, whereas most cell death occurred after 2-3 days. GADD45a upregulation that induces G2 arrest (Chen et al., 2001) was maximum at 72 h. p53-mRNA and target genes including p21 and BAX were not significantly altered by hOTAG-12b (not shown). These indicate that hOTAG12b-induced G2 arrest ( Figure 6 ) and apoptosis could be independent of p53. Western blotting using a phosphop53 antibody also showed only slight increase during apoptosis induced by hOTAG-12b as compared with the effects seen with etoposide ( Figure 8d) . A probable scenario depicting hOTAG-12b's effects on cell cycle arrest and apoptosis is depicted in Supplementary  Figure 5 . arrest of inducible hOTAG-12b cells. Inducible hOTAG-12a, hOTAG-12b subclone and vector-containing cell line were grown with or without 1.6 mg/ml DOX for 48 h. Cells were stained with propidium iodide (PI) and analyzed by FACS. Modified Krishan buffer consists of 0.1% sodium citrate 0.3% NP-40, with 50 mg/ml PI and 20 mg/ml RNase-A (Sigma, St Louis, MO, USA). Results of three different experiments showed a significant proportion of cells arrested at the G2 phase when expressing hOTAG-12b compared with cells expressing hOTAG-12a or the null vector cells.
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OTAG-12b regulates cell sensitivity to apoptotic stimuli We also investigated whether hOTAG-12b induction would lead to increased sensitivity to apoptosis by known anti-cancer agents. In drug-induced apoptosis caused by etoposide and carboplatin, hOTAG-12b's sensitizing effects were more evident (Figures 9a and b) . More cells died if they were pre-exposed to DOXinduced hOTAG-12b, such that a lower concentration and 11 represent no DOX treatment; lanes 2, 7 and 12 represent DOX treatment for 1 day; lanes 3, 8 and 13 represent DOX treatment for 2 days; lanes 4, 9 and 14 represent DOX treatment for 3 days; lanes 5, 10 and 15 represent DOX treatment for 4 days. Ethidium bromide stain of agarose gels with genomic DNA extracted from cells. Molecular weight markers (right first lane) were also included. Very clear DNA ladder formation was found on day 3 of DOX treatment in hOTAG-12b cells, whereas there were no such effects in others. (e) Anchorage-independent assays. 5 Â 10 4 cells were seeded for soft agar assays. DOX was used for protein induction at 1.6 mg/ml for HEK293/TR/OTAG-12a, HEK293/ TR/OTAG-12b subclone and HEK293/TR parental cell line. Dishes were incubated for 10-14 days, colonies stained with 0.005% crystal violet and counted. (f) Results of three different experiments in triplicate were combined; the bar graph shows mean±s.e.m. of three experiments. The colony count was normalized to uninduced cells (no DOX). A significant difference was observed only for cells expressing hOTAG-12b-no colonies (***Po0.001). (g) Suppression of tumorigenesis. 1 Â 10 7 cells were injected subcutaneously into both flanks of 5-6-week-old female nude mice (n ¼ 6-10). After 4 weeks, mice were killed and tumor mass was removed and weighed. Note that tumor size at the site injected with higher hOTAG-12b-expressing clone H is smaller than the site receiving hOTAG-12b-L cells. (h) Tumorigenesis was suppressed by DOX-induced hOTAG-12b but not hOTAG-12a or vector DNA. Tumorigenesis was completely blocked in four out of six injection sites of hOTAG-12b cells. **Po0.01.
Novel ovarian tumor suppressor gene X Chen et al of etoposide (10 mM) that was ineffective by itself now caused profound inhibition (Figure 9b ). hOTAG-12b also sensitized the effect of hygromycin or taxol that cause apoptosis via p53-independent mechanisms; at the concentration tested, these drugs alone did not produce dramatic effects on cells.
Discussion
With the aim of identifying novel genes that might be of value in understanding the etiology of OC that is described as a 'silent killer', we utilized clues emerging from FORKO mice that develop ovarian tumors. Our studies reported herein confirm that the novel OTAG-12 gene downregulated in FORKO tumors as well as mouse epithelial tumors (Figure 1 ) is also downregulated in human OC and established OC cells (Figure 3) . This is the first report to identify and characterize human OTAG-12 and its isoforms in human ovary and OC, and to demonstrate its potent anti-proliferative effects on OC cells. Existence of this gene based on hypothetical bioinformatics predictions had suggested a putative protein indicated as Fam32A with unknown function (NCBI (National Center for Biotechnology Information)). The location of hOTAG-12 on gene-rich human chr. 19 (Grimwood et al., 2004) in proximity to many genes implicated in OC, such as MUC 16 that gives rise to the clinical marker CA 125 for late OC, NOTCH 3, hCG b and other tumor suppressor genes (see Figure 2b) , as well as human disease genes such as LDL-receptor and Apo-E, is noteworthy. Of three variants that were cloned, only hOTAG-12b, the predominant isoform in normal ovary, is active in cell suppression in model systems that include OC cells and xenografts (Figure 1e, Figures 3 and 7) . Present evidence indicates the existence of only the hOTAG-12b form in mouse. The high structural homology between human OTAG-12b and mouse OTAG-12 proteins deduced from our data shows conserved function as both proteins were effective in suppressing OC or HEK293 cells. The variants hOTAG-12a and -12c, which are shorter (107 and 92 residues, respectively) and less abundant in normal ovary, are inactive towards cell suppression. The nuclear location of hOTAG-12b and 12a proteins (Figures 3e and f) is consistent with the presence of a nuclear localization signal in both proteins. As hOTAG-12b and hOTAG-12a differ only in the last 34 amino acids, this domain in hOTAG-12b is apparently important for function as supported by our C-terminal deletion studies (Figure 4) . The F14 and UP domains in hOTAG-12b could be important for interaction with functional partners within the nucleus to exert its inhibitory action. Several experimental manipulations used in this study provide clear evidence that increasing Figure 8 hOTAG-12b induces apoptosis by p53-independent pathway. (a) p53-inducing compounds also increase the expression of hOTAG-12b during apoptosis. UCI107 cells treated by drugs for 24 h (hygromycin-B 800 mg/ml; taxol 3 mM; puromycin 2 mg/ml; etoposide 20 mM; carboplatin 500 mM), RNA was extracted for Q-PCR. (b) SKOV3 (p53-null and platinum-resistant OC cell line) apoptosis induced by hOTAG-12b transfection. SKOV3 cells were transfected with OTAG-12a, OTAG-12b and pIRES2 vector using Lipofectamine 2000, then cultured in 1000 mg/ml G418 for 2-3 weeks. (c) hOTAG-12b induced apoptosis by upregulation of proapoptosis gene BAD, CIDEB, and GADD45a and downregulation of pro-survival gene Akt1 and NAIP. Each of the bars represents the mean±s.e.m. from three separate experiments; *Po0.05; **Po0.01 compared with control. (d) Lack of significant phosphorylation of p53 upon DOX induction of OTAG-12b in HEK293 cells. Phospho-p53 was assessed in cell lysates at different times using a specific antibody (Ser15, Cell Signaling Technology Inc., Danvers, MA, USA). In the control HEK293 cells that were treated only by etoposide (ET), robust phosphorylation of p53 is evident after 6 h (left of d).
Novel ovarian tumor suppressor gene X Chen et al the level of OTAG-12b protein suppresses cell growth by inhibiting cell proliferation, inducing G2 cell cycle arrest, and also by promoting apoptosis. Such functions have also been reported for tumor suppressor genes such as IRF-5 (Barnes et al., 2003) .
Owing to its potent cell-suppressing effects, we were unable to secure stable clones of OC cells or HEK293-expressing hOTAG-12b or mouse-OTAG-12, whereas this difficulty was not encountered for hOTAG-12a (not shown). Others have reported a similar inability for overexpression of wild-type gene and for establishing cell lines for tumor suppressors such as OVCA1 (Bruening et al., 1999) and RPS6KA2 (Bignone et al., 2007) in OC cells. This led us to generate DOXcontrolled strategies that resulted in securing a workable system with HEK293 cells and providing an experimental tool to manipulate hOTAG-12b expression and explore mechanistic issues.
Using DOX-controlled expression, we reveal that elevated hOTAG-12b effects can be reversed following termination of gene induction. Other evidence includes the fact that a related protein such as hOTAG-12a differing only in the carboxyl-terminus and providing a natural control is not detrimental to cells. Our C-terminal deletion studies of hOTAG-12 (Figure 4 ) also lend additional support to the fact that apoptotic effects are unique to the whole structure and are of physiological/pathological significance.
Addressing the molecular nature of cellular inhibition, we have found that hOTAG-12b stimulates expression of several pro-apoptotic genes such as BAD (Willis and Adams, 2005; Boisvert-Adamo and Aplin, 2008) , CIDEB (Lugovskoy et al., 1999; Chen et al., 2000) and GADD45a (Thyss et al., 2005; Al-Romaih et al., 2008) , and inhibits expression of anti-apoptotic genes such as NAIP (Liston et al., 2003; O'Riordan et al., 2008) and Akt1 (Zhu et al., 2008) . hOTAG-12b, similar to p53, induces a set of overlapping genes such as GADD45a and distinct genes such as Akt1, BAD, CIDEB and NAIP. Although p53-inducing compounds in OC cells (Figure 8a ) could stimulate the expression of endogenous hOTAG-12b, transfection of hOTAG-12b by itself does not stimulate p53 or its direct target genes such as p21 and BAX. These results suggest that hOTAG-12b induces apoptosis via a p53-independent pathway (a result confirmed by overexpression of hOTAG-12b in p53-null cell line-SKOV3 cells); however, we could not exclude hOTAG-12b inducing apoptosis through p53 downstream signaling. Our current working model for hOTAG-12b's effects depicted in the scheme (Supplementary Figure 5) includes the cumulative effect of opposing pathways-activation of cell cycle arrest and apoptosis and inhibition of cellular proliferation. Although the target gene(s) responsible for the primary effect of expression of hOTAG-12b remains unclear, stimulated expression of GADD45a as early as 12 h after DOX induction (Figure 8c ) is noteworthy. GADD45a is also regulated by a p53-independent pathway (Chen et al., 2001; Zhu et al., 2008) . In addition, GADD45a, a known transcriptional target of BRCA1 (Harkin et al., 1999) , is responsible at least in part for the regulation of a G2 cell cycle checkpoint (Wagner et al., 2008) .
The in vivo effects of hOTAG-12b on xenografts in nude mice (Figures 7g and h ) suggest good potential for tumor abrogation. In addition, data emerging from our Figure 9 hOTAG-12 regulates the sensitivity of cells to apoptotic stimuli. The stable clones of hOTAG-12a, hOTAG-12b and vector were left untreated or treated with DOX for 24 h (removed after that) and then subjected to the following treatments for another 20 h: (a) Etoposide-(topoisomerase II inhibitor) as an example at the concentration indicated. Cells were stained by trypan blue. (b) Etoposide-ET, Carboplatin-CB, Hygromycin-HM and Taxol-TA stimulation. A total of 7000 cells were seeded in 96-well plates with medium change after 1 day for treatment with or without DOX for 24 h. Following DOX removal, cells were exposed to the compounds. In each case, the number of cells was determined by MTT assay. Each bar represents mean ± s.e.m. from three separate experiments; ***Po0.001 compared with DOX treatment only.
Novel ovarian tumor suppressor gene X Chen et al study on combinatorial effects of hOTAG-12b and anticancer agents in enhancing cellular sensitivity are interesting for practical considerations (Figure 9 ). This assumes importance because drug resistance is the main clinical issue confronting OC. Although 75% of patients with advanced disease respond to initial (carboplatincontaining) chemotherapy, the majority will relapse and 25% of patients are intrinsically resistant, that is, will not respond to chemotherapy at all (Bast Jr et al., 2009) . One approach to overcoming resistance in EOC is to reactivate pro-apoptosis pathways. Chemoresistant OC cells become sensitive to cisplatin-induced apoptosis following PTEN overexpression (Yan et al., 2006) . Thus, discovery of a novel cell suppressor like hOTAG12b is important because induction of tumor cell senescence may represent a therapeutic approach for cancer. This would require strategies to upregulate hOTAG-12b gene expression or protein delivery. As hOTAG-12b is the simplest protein among all currently known ovarian tumor suppressors (Bast Jr et al., 2009) , the prospects for bio-engineering appear favorable.
To further elucidate the role of OTAG-12 in OC, generating variant-specific antibodies could help future studies for analyzing the protein in tumors including heritable cases. Securing OTAG-12-null mice will help address issues in development and function. Understanding transcriptional control and silencing of hOTAG-12b in tumors and the biochemical basis of its function in inhibiting cell growth as well as cellular localization or alteration in cancers would also be important.
Materials and methods

Cell lines and culture conditions
The following cells used in this study-HC11-26 mammary tumor cells (Dr Jolicoeur), ID8 mouse ovarian epithelial cells (Dr Roby), OC cells UCI101, UCI107 cells (Dr Carpenter), SKOV3, OVCAR3 and OVCAR4 (ATCC), HEK293 (ATCC CRL-1573, transformed with adenovirus-5 DNA)-were grown in the medium according to the provider's recommendations.
RNA isolation and cDNA preparation and RT-PCR and Q-PCR RNA was isolated from human ovarian samples (collected by Gotlieb lab) as well as cell lines, using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Total RNA (2 mg) was reverse transcribed using SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA), and Oligo-dT. Reverse transcriptase-PCR (RT-PCR) and Q-PCR were performed as described (Aravindakshan et al., 2010) .
Gene cloning-RACE
To obtain full-length 5 0 and 3 0 ends of cDNA using the sequence from expressed sequence tags, RACE was performed using GeneRacer Kit (Invitrogen). After cloning RACE products, both DNA strands were sequenced.
Transfection and colony formation assays
A cDNA fragment containing each OTAG-12 ORF was cloned into vector pIRES2 (Clontech Laboratories, Mountain View, CA, USA), with V5 and GFP tag. pIRES2-expressing OTAG-12 or empty vector as control was transfected using Lipofectamine 2000 (Invitrogen). Carboxyl deletion mutants of hOTAG-12b were generated by PCR using the primers indicated in Supplementary Table 1 and cloned into the same  vector for cell transfections. For anchorage-dependent assay, at 24 h post-transfection, cells were trypsinized, washed, diluted 1/10 and seeded onto six-well plates in media containing G418 (400-1200 mg/ml) for selection. Cells were grown for 2-3 weeks; colonies were stained with 0.1% Coomassie blue and counted. At least three experiments were performed in quadruplicate for each cell line.
DOX-controlled expression system
Inducible stable cell lines overexpressing the gene of interest under the control of Tet-repressor were generated using T-REX Tetracycline-Regulated Mammalian Expression System (provided by Dr Jolicoeur). The rtTA retrovirus for expression of tetracycline repressor protein (TetR) has puromycin selection. Each gene was cloned in LITMUS 29/ TO (G418 resistance). HEK293 and UCI101/107 cells were transfected simultaneously or sequentially with repressor and expression vectors using Lipofectamine 2000. Transfected cells were selected in the presence of 2 mg/ml puromycin and 600-1000 mg/ml G418 for 2-3 weeks. Individual clones were expanded and tested for expression of transfected gene in the presence of DOX.
Proliferation assay-MTT
In total, 2000 cells were plated onto a 96-well plate in Dulbecco's modified Eagle's medium-10% fetal bovine serum and left to adhere. After 24 h, 1.6 mg/ml DOX was added. Proliferation was measured by MTT assay (Vybrant MTT Cell Proliferation Assay Kit, Invitrogen). Absorbance was measured at 570 nm. At least three experiments were performed in quadruplicate.
Soft agar assays
To assess anchorage-independent growth, we mixed the cells at 37 1C with 0.4% agarose in complete medium and poured the mixture over a layer of 0.8% agarose in six-well plates. After 15 min at room temperature, plates were incubated at 37 1C for 2-3 weeks. They were then stained by p-iodonitrotetrazolium violet and incubated at 37 1C for 6 h, after which colonies were photographed and counted using microscope-associated software.
Assessment of cell viability
Cell viability was determined by examining the apoptotic morphology of nuclear staining with hematoxylin or Hoechst 33342 (Sigma) as described (Allen et al., 2001) .
Fragmentation by DNA ladder DNA ladder formation in DOX-inducible clones was determined as described by Wu et al. (2005) . DNA fragments were separated on a 1.5% agarose gel, visualized with ethidium bromide and photographed.
Fluorescence-activated cell sorting apoptosis assay The induction of apoptosis by OTAG-12 was assessed by Annexin V-APC assay according to the manufacturer's instructions (Annexin V-APC Apoptosis Detection Kit, EBioscience, San Diego, CA, USA). Vector, hOTAG-12a and hOTAG-12b HEK293-inducible stable clone cells were Novel ovarian tumor suppressor gene X Chen et al incubated with or without 1.6 mg/ml DOX for 1, 2 and 3 days. Detached cells were labeled with Annexin V-APC. PI was added to stain necrotic, dead and membrane-compromised cells. Cells were analyzed by fluorescence-activated cell sorting of 10 000 events. A log FL1 (X-axis) versus log FL3 (Y-axis) dot plot was generated.
Cell cycle analysis
Cell cycle analysis was done according to the modified Krishan procedure. Briefly, 1 Â 10 6 DOX-inducible stable cells were washed and resuspended in 1 ml of modified Krishan staining buffer (see Figure 6b ). Cells were analyzed by FACS (Becton Dickenson, Cowley, UK) using MODFIT LT for MACPPC software. A total of 10 000 single events were recorded each time, and the percentage of cells in G1, G2 and S phases was calculated. The experiments were repeated at least three times for each variable.
Total protein extraction and subcellular fractionation Cell lysates for western blotting were prepared as described (Chen et al., 2006) . Cytoplasmic and nuclear fractions were prepared according to Dai et al. (2009) .
Immunohistochemistry Subcellular localization in transfected cells was performed using the V5 antibody and standard methods as employed in our laboratory (Aravindakshan et al., 2006b) .
Tumorigenicity assay
Cells grown in log-phase and harvested by trypsinization were washed twice with PBS and resuspended in Dulbecco's modified Eagle's medium to a final concentration of 3.3 Â 10 7 / ml. The cells (1 Â 10 7 cells in 300 ml PBS/site) were injected subcutaneously into both flanks of 5-to 6-week-old female nude mice (nu/fox1, Harlan Laboratories, Indianapolis, IN, USA). A total of 10 sites were tested for each cell line and tumor growth in animals (n ¼ 10) was checked weekly. In all, 2 mg/ml DOX was added to the drinking water 1 day before injection and changed twice a week. After 4 weeks, mice were killed, and tumor mass at each location was measured. All procedures were carried out with approval by the Institutional Animal Care and Use Committee.
Cell sensitization UCI101 and UCI107 cells were grown 10 6 /well in six-well plates and treated with or without the compounds for 24 h. HEK293-inducible stable cells were treated by DOX for 24 h and washed with Hank's balanced salt solution, then incubated with or without compounds.
Statistics
Student's t test was done to assess significance (Po0.05). Data are shown as mean ± s.e.m.
